Checkpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Checkpoint Capital L.P. acquired 9,011 shares of Immunocore Holdings PLC valued at approximately $267,000, making it the company's 13th largest position.
• Other institutional investors, including Banque Transatlantique and Frazier Life Sciences Management, have also increased their stakes in Immunocore during the first quarter.
• Immunocore reported a revenue of $130.65 million for the last quarter, beating analyst estimates as the company continues to develop immunotherapies for cancer and other diseases.

Checkpoint Capital L.P. bought a new stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 9,011 shares of the company's stock, valued at approximately $267,000. Immunocore accounts for 0.1% of Checkpoint Capital L.P.'s holdings, making the stock its 13th largest position.

A number of other institutional investors also recently modified their holdings of the stock. Banque Transatlantique SA acquired a new stake in shares of Immunocore during the 1st quarter valued at $278,000. Frazier Life Sciences Management L.P. boosted its stake in shares of Immunocore by 176.9% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 301,170 shares of the company's stock valued at $8,936,000 after buying an additional 192,408 shares during the period. Baker BROS. Advisors LP boosted its stake in shares of Immunocore by 53.3% during the 1st quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company's stock valued at $68,913,000 after buying an additional 807,338 shares during the period. Royal Bank of Canada boosted its stake in shares of Immunocore by 45.1% during the 1st quarter. Royal Bank of Canada now owns 44,011 shares of the company's stock valued at $1,306,000 after buying an additional 13,689 shares during the period. Finally, Tema Etfs LLC lifted its stake in shares of Immunocore by 37.8% in the 1st quarter. Tema Etfs LLC now owns 15,428 shares of the company's stock valued at $458,000 after purchasing an additional 4,234 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Stock Up 9.3%

Immunocore stock opened at $35.27 on Thursday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -88.18 and a beta of 0.77. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86. Immunocore Holdings PLC Sponsored ADR has a fifty-two week low of $23.15 and a fifty-two week high of $39.33. The firm has a fifty day moving average price of $33.44 and a two-hundred day moving average price of $31.45.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. The firm had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The business's revenue was up 30.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.23) EPS. As a group, analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price objective for the company. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Jefferies Financial Group assumed coverage on shares of Immunocore in a research note on Monday, August 25th. They issued a "buy" rating and a $48.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research note on Monday, June 2nd. Finally, Oppenheimer lifted their price objective on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $56.89.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.